# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT See9c7977ec
CUTOFF DATE (today): 2024-01-23
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-11-01 | official-forward (B) | draft_guidance_availability_notice | "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring and recording growth and evaluating pubertal development for drugs or biological products in development for pediatric use when such an assessment is necessary to support safety. This draft guidance is intended to encourage a consistent approach to collecting interpretable and accurate growth and pubertal development data. This draft guidance does not address use of growth or pubertal development data to support primary evidence of efficacy in growth disorders and does not address evaluation of nutritional status.
---
## SNAPSHOT Sc4c8c0132c
CUTOFF DATE (today): 2024-10-02
Regulator: FDA (US)
Matter: FDA draft guidance: Mpox: Development of Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT See1ab75ec2
CUTOFF DATE (today): 2022-04-27
Regulator: FDA (US)
Matter: FDA draft guidance: General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-08-01 | official-forward (B) | draft_guidance_availability_notice | "General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products." This draft guidance is intended to assist sponsors of new drug applications
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products." This draft guidance is intended to assist sponsors of new drug applications (NDAs), biologics license applications (BLAs) for therapeutic biologics, and supplements who are planning to conduct clinical studies in neonatal populations. The issuance of this draft guidance on clinical pharmacology considerations for neonatal studies for drugs and biological products is stipulated under the FDA Reauthorization Act of 2017 (FDARA).
---
## SNAPSHOT S427043de05
CUTOFF DATE (today): 2026-07-07
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing the pre-open call auction price-discovery mechanism for IPO listings and re-listed scrips
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-21 | official-forward (B) | consultation_paper | "Consultation Paper on Review of price discovery mechanism through Pre-open Call Auction Session for IPO and Re-listed scrips" | www.sebi.gov.in
   Claims: Seeks comments on reviewing the price-discovery mechanism of the Pre-open Call Auction Session used for IPO listings and re-listed scrips. / Describes the existing 60-minute session structure (45 min order entry/modification/cancellation, 10 min matching, 5 min buffer) with random closure between the 35th and 45th minute. / Notes there is currently no price band in this Call Auction Session and that market orders are not allowed. / Frames the review as addressing price-discovery/volatility concerns on the day of listing or re-listing.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to review the price discovery mechanism through Pre-open Call Auction Session (hereinafter referred as 'Call Auction Session') for IPO and re-listed scrips on the date of their listing or re-listing. A Call Auction Session for IPO and re-listed scrips was introduced by SEBI vide its circular No. CIR/MRD/DP/01/2012 dated January 20, 2012.
---
## SNAPSHOT S323e65094b
CUTOFF DATE (today): 2021-05-24
Regulator: FDA (US)
Matter: FDA draft guidance: Premenopausal Women With Breast Cancer: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-10-08 | official-forward (B) | draft_guidance_availability_notice | "Premenopausal Women With Breast Cancer: Developing Drugs for Treatment; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Premenopausal Women with Breast Cancer: Developing Drugs for Treatment." This draft guidance provides recommendations regarding the inclusion of premenopausal women in breast ca
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Premenopausal Women with Breast Cancer: Developing Drugs for Treatment." This draft guidance provides recommendations regarding the inclusion of premenopausal women in breast cancer clinical trials. The guidance is intended to assist stakeholders, including sponsors and institutional review boards, responsible for the development and oversight of clinical trials for breast cancer drugs.
---
## SNAPSHOT S35c09da3b5
CUTOFF DATE (today): 2026-06-12
Regulator: SEBI (IN)
Matter: SEBI consultation: recognizing intraday borrowing facilities as a cash-management tool for mutual funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-13 | official-forward (B) | consultation_paper | "Consultation Paper on utilization of intraday borrowing lines by Mutual Funds" | www.sebi.gov.in
   Claims: Proposes to recognize intraday borrowing facilities used by mutual funds as a cash-management tool, with necessary safeguards and consistency across AMCs. / Notes an intraday-borrowing carve-out already exists in SEBI (Mutual Funds) Regulations, 2026 (effective April 1, 2026) and related March 13, 2026 circular safeguards, for the specific purpose of meeting redemption/unitholder payouts. / States the applicability of the existing intraday-borrowing guidelines had been deferred to July 15, 2026 due to operational challenges raised by AMFI/AMCs. / Based on AMFI representations on using intraday borrowing to bridge timing gaps between redemption payouts and receipt of guaranteed receivables from GoI/RBI/CCIL.
   Excerpt: The objective of this consultation paper is to solicit comments on the proposal to recognize intraday borrowing facilities utilized by Mutual Funds as a cash management tool, consider necessary safeguards and consistency in practices among Mutual Funds. Based on representation made by Association of Mutual Funds in India (AMFI) on intraday borrowing arrangement by mutual funds to bridge the timing gap between redemption payouts and receipt of guaranteed receivables due on the same day from Government of India (GoI), Reserve Bank of India (RBI) and Clearing Corporation of India Limited (CCIL), a carve out for intraday borrowings was enabled in SEBI (Mutual Funds) Regulations, 2026.
---
## SNAPSHOT S547a007897
CUTOFF DATE (today): 2023-03-14
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Scfadf319e2
CUTOFF DATE (today): 2023-11-21
Regulator: FDA (US)
Matter: FDA draft guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S1d454d6502
CUTOFF DATE (today): 2026-09-17
Regulator: SEBI (IN)
Matter: SEBI consultation: proposed amendments to the certification regime for associated persons in the securities markets
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S45bf611f40
CUTOFF DATE (today): 2025-06-18
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S04e744e9eb
CUTOFF DATE (today): 2025-12-10
Regulator: SEBI (IN)
Matter: SEBI consultation: easing IPO lock-in mechanics for pledged shares and requiring an abridged prospectus at the draft-offer-document stage
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-11-13 | official-forward (B) | consultation_paper | "Consultation Paper on amendments to SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, with the objective of enhancing ease of doing business and increasing the participation of retail investors in pu" | www.sebi.gov.in
   Claims: Proposes that where lock-in cannot technically be created on pledged pre-issue shares, depositories instead record such shares as 'non-transferable' for the lock-in duration, with automatic re-imposition of lock-in on the pledger/pledgee after pledge release. / Proposes requiring a standardized, concise abridged prospectus already at the draft offer document (DRHP) stage, in addition to the existing requirement at the RHP (offer document) stage. / States the objective is to enhance ease of doing business for issuers and increase retail-investor participation and comprehension in the IPO process.
   Excerpt: This consultation paper seeks comments / suggestions from the public on the following proposals relating to amendments to SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, ('ICDR Regulations') with the objective of enhancing ease of doing business and increasing the participation of retail investors in public issue: 1.1.1. Review of the requirement of lock-in of shares at the time of Initial Public Offer ('IPO'). 1.1.2. Review of the requirement of Abridged Prospectus. Part A - Review of the requirement of lock-in of shares at the time of IPO... The existing system of the depositories does not allow lock-in of certain shares such as those under pledge.
---
## SNAPSHOT S049340c933
CUTOFF DATE (today): 2026-06-10
Regulator: SEBI (IN)
Matter: SEBI consultation: revising the method for calculating variable net worth of stock brokers
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S2470fcaecb
CUTOFF DATE (today): 2022-01-23
Regulator: FDA (US)
Matter: FDA draft guidance: Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-10-14 | official-forward (B) | draft_guidance_availability_notice | "Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availab" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of the draft guidance entitled "Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices; Draft Guidance for Industry and Food a
   Excerpt: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of the draft guidance entitled "Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices; Draft Guidance for Industry and Food and Drug Administration Staff." This draft guidance explains that there are certain class I devices for which FDA does not intend to enforce Global Unique Device Identification Database (GUDID) submission requirements and describes how a labeler of a class I device can determine if its device is one of these devices in the revised section III of this draft guidance. When this draft guidance is finalized, the updates in section III of this draft guidance would supersede the recommendations in section III of the guidance "Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices and Certain Devices Requiring Direct Marking" ("2020 UDI Compliance Policy Guidance," available at: https:// www.fda.gov/regulatory-information/search-fda-guidance-documents/ unique-device-identification-policy-regarding-compliance-dates-class-i- and-unclassified-devices-an
---
## SNAPSHOT Sd68f52aa3c
CUTOFF DATE (today): 2023-02-13
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sbe37fd80a6
CUTOFF DATE (today): 2026-03-16
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business measures for Real Estate Investment Trusts and Infrastructure Investment Trusts
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6bb8777881
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: enhancements to the Straight-Through Processing framework for institutional trade messaging
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-19 | official-forward (B) | consultation_paper | "Consultation Paper on Easing of framework for Straight Through Processing (STP) of trades" | www.sebi.gov.in
   Claims: Seeks feedback on enhancements to the existing Straight-Through Processing (STP) framework to reduce latency and costs and enhance service delivery for market participants. / Describes STP as automating end-to-end processing of financial-instrument transactions, including Electronic Contract Notes (ECNs), across stock brokers, custodians and institutional investors. / Notes the existing STP architecture (involving Sender/Receiver STP Service Providers, 'SSPs') traces to SEBI circulars dated Feb 3 2004, Feb 25 2004, Apr 1 2004 and May 26 2004. / Identifies issues with the current STP architecture where different SSPs are used by each STP user.
   Excerpt: The objective of the consultation paper is to seek feedback on the enhancements in the existing Straight-Through Processing (STP) Framework to reduce the latency, costs and enhance service delivery for market participants. STP automates the end-to-end processing of transactions of the financial instruments. It involves use of a single system to process or control all elements of the work-flow of a financial transaction.
---
## SNAPSHOT S86a2181d44
CUTOFF DATE (today): 2025-11-17
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting debt issuers to offer incentives to certain categories of investors in public issues
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S89697dca81
CUTOFF DATE (today): 2023-06-09
Regulator: FDA (US)
Matter: FDA draft guidance: Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S32c25d9b4b
CUTOFF DATE (today): 2024-08-21
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sa858e6e87d
CUTOFF DATE (today): 2023-02-08
Regulator: FDA (US)
Matter: FDA draft guidance: Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-12-01 | official-forward (B) | draft_guidance_availability_notice | "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific 
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications." This draft guidance focuses on specific recommendations pertinent to gastric pH- dependent drug-drug interaction (DDI) assessment and describes the FDA's recommendations regarding when clinical DDI studies with acid- reducing agents (ARAs) are needed; design of the clinical studies; interpretation of study results; and communicating findings and options for managing pH-dependent DDIs in product labeling.